Opinion

Video

Closing

Fact checked by:

Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.

Video content above is prompted by the following:

  • How do minimally invasive surgical therapies (MIST) options fit into the evolving landscape of treatments for benign prostate dysplasia; why should urologists consider MIST options for their patients?
  • What unmet needs remain in the treatment of BPH, and are there any current trials/investigations in these topics?
Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.